HK1103105A1 - Non-tumorigenic mdck cell line for propagating viruses - Google Patents

Non-tumorigenic mdck cell line for propagating viruses

Info

Publication number
HK1103105A1
HK1103105A1 HK07110669A HK07110669A HK1103105A1 HK 1103105 A1 HK1103105 A1 HK 1103105A1 HK 07110669 A HK07110669 A HK 07110669A HK 07110669 A HK07110669 A HK 07110669A HK 1103105 A1 HK1103105 A1 HK 1103105A1
Authority
HK
Hong Kong
Prior art keywords
cell lines
present
cell line
viruses
production
Prior art date
Application number
HK07110669A
Other languages
English (en)
Inventor
Richard Schwartz
John Michael Berry
Ajit Subramanian
Xiao Shi
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1103105A1 publication Critical patent/HK1103105A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/02—Separating microorganisms from their culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK07110669A 2004-12-23 2007-10-03 Non-tumorigenic mdck cell line for propagating viruses HK1103105A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63816604P 2004-12-23 2004-12-23
US64113905P 2005-01-05 2005-01-05
PCT/US2005/045587 WO2006071563A2 (en) 2004-12-23 2005-12-16 Non-tumorigenic mdck cell line for propagating viruses

Publications (1)

Publication Number Publication Date
HK1103105A1 true HK1103105A1 (en) 2007-12-14

Family

ID=36615395

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07110669A HK1103105A1 (en) 2004-12-23 2007-10-03 Non-tumorigenic mdck cell line for propagating viruses
HK12102910A HK1162587A1 (en) 2004-12-23 2007-10-03 Non-tumorigenic mdck cell line for propagating viruses mdck

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12102910A HK1162587A1 (en) 2004-12-23 2007-10-03 Non-tumorigenic mdck cell line for propagating viruses mdck

Country Status (12)

Country Link
US (3) US7670837B2 (xx)
EP (2) EP2368975B1 (xx)
JP (2) JP5414178B2 (xx)
KR (2) KR101260084B1 (xx)
CN (2) CN101189326B (xx)
AT (1) ATE547511T1 (xx)
AU (1) AU2005322353B2 (xx)
CA (1) CA2592120A1 (xx)
DK (1) DK2368975T3 (xx)
ES (2) ES2526170T3 (xx)
HK (2) HK1103105A1 (xx)
WO (1) WO2006071563A2 (xx)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816222A1 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1976559B3 (en) 2006-01-27 2020-02-19 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
CN101472941B (zh) 2006-03-31 2017-08-08 沃弗-威斯康星校友研究基金会 用于疫苗的高滴度重组流感病毒
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
EP2069482A4 (en) * 2006-10-17 2011-08-24 Medimmune Llc INFLUENCE OF VIRAL FAT COMPONENTS
EP1923070A1 (en) * 2006-11-15 2008-05-21 Intervet International BV Vaccine for vaccinating feline against influenza virus
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
CN101688186A (zh) * 2007-05-04 2010-03-31 巴克斯特国际公司 用于病毒增殖的两阶段温度分布
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EP2185191B1 (en) 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP5415449B2 (ja) 2007-12-24 2014-02-12 ノバルティス アーゲー 吸着されたインフルエンザワクチンのためのアッセイ
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
AU2009268576B2 (en) * 2008-07-11 2014-03-27 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
US8202726B2 (en) * 2008-09-24 2012-06-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
ES2608841T3 (es) 2009-02-10 2017-04-17 Seqirus UK Limited Vacunas contra la gripe con cantidades reducidas de escualeno
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
JP5717657B2 (ja) 2009-03-13 2015-05-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系ボツリヌス毒素血清型ａ活性アッセイに有用な細胞
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
WO2010125461A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
JP5740392B2 (ja) 2009-05-08 2015-06-24 ノバルティス アーゲー インフルエンザウイルスを検出するための一般的なアッセイ
WO2010133964A1 (en) 2009-05-21 2010-11-25 Novartis Ag Reverse genetics using non-endogenous pol i promoters
KR20120039047A (ko) 2009-07-31 2012-04-24 노파르티스 아게 역유전학 시스템
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
US8883481B2 (en) 2009-10-20 2014-11-11 Novartis Ag Reverse genetics methods for virus rescue
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
FR2956409A1 (fr) 2010-02-15 2011-08-19 Univ Claude Bernard Lyon Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale
WO2011110955A2 (en) 2010-03-08 2011-09-15 Novartis Ag Methods of testing for intracellular pathogens
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2011205968A (ja) * 2010-03-30 2011-10-20 Iwate Medical Univ 細胞培養によるインフルエンザワクチンの製造方法
TW201202425A (en) 2010-04-28 2012-01-16 Abbott Biologicals Bv Production of viral components
WO2011134163A1 (zh) * 2010-04-29 2011-11-03 扬州优邦生物制药有限公司 一种h9n2亚型禽流感灭活疫苗的制备方法及产品
CN102946727B (zh) 2010-05-06 2015-08-19 诺华有限公司 微生物灭活的有机过氧化物化合物
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
PT2575872T (pt) 2010-06-01 2020-11-19 Seqirus Uk Ltd Concentração de antigénios da vacina da gripe sem liofilização
NZ603863A (en) 2010-06-01 2014-09-26 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
EP2606128B1 (de) * 2010-08-16 2014-09-10 CEVEC Pharmaceuticals GmbH Permanente humane amniozyten zellinie zur herstellung von influenzaviren
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012033236A1 (ko) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
US9657359B2 (en) 2010-09-07 2017-05-23 Novartis Ag Generic assays for detection of mamalian reovirus
TWI537385B (zh) * 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
FR2971517B1 (fr) * 2011-02-10 2013-05-31 Univ Claude Bernard Lyon Composition pour supplementer des milieux de culture cellulaire
CA2828192A1 (en) 2011-02-25 2012-08-30 Novartis Ag Exogenous internal positive control
CN102181449B (zh) * 2011-03-06 2013-04-10 浙江大学 表达人有机阳离子转运体1的细胞模型构建及应用
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US20140335507A1 (en) 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
CN102526720B (zh) * 2012-01-11 2013-12-11 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒疫苗的制备方法
EP2820126B1 (en) 2012-03-02 2017-05-17 Seqirus UK Limited Influenza virus reassortment
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
CN105120893B (zh) 2012-12-03 2018-11-13 诺华股份有限公司 流感病毒重配
EP2968512A2 (en) 2013-03-13 2016-01-20 Novartis AG Influenza b virus reassortment
CN104059873B (zh) * 2013-03-20 2016-09-28 上海生物制品研究所有限责任公司 用于扩增流感病毒的非致瘤性mdck细胞系及其筛选方法
CN103215219A (zh) * 2013-04-24 2013-07-24 哈尔滨市疾病预防控制中心 一种mdck细胞改良传代方法
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
WO2015017673A1 (en) * 2013-08-01 2015-02-05 Medimmune, Llc Methods for producing influenza vaccine compositions
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
GB201321679D0 (en) * 2013-12-09 2014-01-22 Vibralogics Gmbh Method of culturing vero cells
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
KR20230132628A (ko) 2015-07-07 2023-09-15 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
TWI781915B (zh) * 2015-10-30 2022-11-01 財團法人國家衛生研究院 用於疫苗製備之於無血清、化學性界定培養基中之mdck懸浮細胞株
EP3417056A1 (en) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Improved influenza b virus replication for vaccine development
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
EP3420076B1 (en) 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
WO2018161858A1 (en) 2017-03-06 2018-09-13 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
CN108524929B (zh) * 2017-03-06 2019-05-07 广州瑞贝斯药业有限公司 一种狂犬病疫苗的生产方法
CN107236699A (zh) * 2017-05-18 2017-10-10 武汉博士德生物工程有限公司 一种用于贴壁培养细胞的培养基及其应用
KR102453351B1 (ko) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
CN109852579A (zh) * 2019-03-27 2019-06-07 西北民族大学 无血清悬浮培养型mdck细胞株及其应用
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US20230000971A1 (en) 2019-11-18 2023-01-05 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
CN111440762B (zh) * 2020-04-14 2020-12-04 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种全悬浮mdck细胞和利用全悬浮mdck细胞培养猪流感病毒的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5118513A (en) 1987-07-02 1992-06-02 The Procter & Gamble Company Method for enhancing bioavailability of iron-calcium mineral supplements
US5035614A (en) 1990-01-17 1991-07-30 Tp Orthodontics, Inc. Intruding and torquing auxiliary
SU1698288A1 (ru) 1990-02-01 1991-12-15 Всесоюзный научно-исследовательский институт гриппа Штамм VIRUS INFLUeNZa А/Ленинград/325/88 дл приготовлени гриппозного диагностикума
US6245549B1 (en) 1990-06-28 2001-06-12 Connaught Laboratories Limited Production of virus and purification of viral envelope proteins for vaccine use
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
EP0953041A4 (en) * 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
ES2226383T3 (es) * 1998-04-17 2005-03-16 Societe Des Produits Nestle S.A. Linea de celulas inmortalizadas derivadas de tejidos cutaneos humanos normales.
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
WO2001016294A2 (en) 1999-08-27 2001-03-08 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
CA2401117C (en) * 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
CA2319205A1 (en) 2000-03-13 2001-09-13 The State Of Oregon Acting By And Through The State Board Of Higher Educ Ation On Behalf Of Oregon State University High-throughput microbial culturing
KR100862758B1 (ko) 2000-04-28 2008-10-13 세인트 쥬드 칠드런즈 리써치 호스피탈 감염성 인플루엔자 바이러스 생성용 ｄｎａ 트랜스펙션시스템
DK1297110T3 (da) * 2000-06-23 2009-11-16 Intervet Int Bv Attenueret bovin respiratorisk syncytialvirus
US20040241139A1 (en) 2000-07-20 2004-12-02 Gerd Hobom Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
EP1465987B1 (en) * 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
JP2005523698A (ja) 2002-04-26 2005-08-11 メディミューン・ヴァクシンズ・インコーポレーテッド インフルエンザウイルスの生産用多重プラスミドシステム
EP1520008B1 (en) * 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
CA2496918A1 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
CA2517181C (en) 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
WO2004083397A2 (en) * 2003-03-18 2004-09-30 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
WO2004110484A1 (fr) 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Procede de production d'un vaccin vivant de culture contre le virus de la grippe
US20050035614A1 (en) 2003-08-11 2005-02-17 Ralph Wessel Light bulb puller
WO2005026333A1 (ja) 2003-09-09 2005-03-24 Japan Science And Technology Agency プロテアーゼを用いた接着性細胞の浮遊培養技術、及び該細胞を宿主として用いてウィルスを生産する方法
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
AU2005217154B2 (en) * 2004-03-01 2010-02-18 Ares Trading S.A. Use of a serum-free cell culture medium for the production of IL-18BP in mammalian cells
JP4650798B2 (ja) 2004-04-19 2011-03-16 デンカ生研株式会社 ウイルスの生産方法
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
DK2368975T3 (en) * 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
CA2601006C (en) 2005-03-10 2012-10-23 Kyoritsu Seiyaku Corporation Cell strain capable of being cultured without ingredients derived from animals, method of producing the same, method of producing virus using the same, and method of producing vaccine
US7534596B2 (en) * 2006-02-10 2009-05-19 Solohill Engineering, Inc. Method and device for producing vaccine
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
EP1982727A1 (en) 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for purification of viral proteins
US8202726B2 (en) 2008-09-24 2012-06-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses

Also Published As

Publication number Publication date
US20060188977A1 (en) 2006-08-24
WO2006071563A3 (en) 2006-12-14
US20120115206A1 (en) 2012-05-10
EP1831353A2 (en) 2007-09-12
JP2012210225A (ja) 2012-11-01
JP5414178B2 (ja) 2014-02-12
EP2368975B1 (en) 2014-09-17
US8119388B2 (en) 2012-02-21
ATE547511T1 (de) 2012-03-15
CN101189326A (zh) 2008-05-28
US7670837B2 (en) 2010-03-02
KR101323459B1 (ko) 2013-10-29
ES2382557T3 (es) 2012-06-11
EP2368975A1 (en) 2011-09-28
JP2008525025A (ja) 2008-07-17
CN103555670A (zh) 2014-02-05
EP1831353A4 (en) 2009-03-25
JP5469710B2 (ja) 2014-04-16
KR20120137442A (ko) 2012-12-20
CN103555670B (zh) 2015-08-12
KR101260084B1 (ko) 2013-05-03
US8748174B2 (en) 2014-06-10
HK1162587A1 (en) 2012-08-31
KR20070098998A (ko) 2007-10-08
WO2006071563A2 (en) 2006-07-06
ES2526170T3 (es) 2015-01-07
US20100112000A1 (en) 2010-05-06
CA2592120A1 (en) 2006-07-06
AU2005322353B2 (en) 2011-09-01
DK2368975T3 (en) 2015-01-05
EP1831353B1 (en) 2012-02-29
AU2005322353A1 (en) 2006-07-06
CN101189326B (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
HK1103105A1 (en) Non-tumorigenic mdck cell line for propagating viruses
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
WO2006127768A3 (en) Microscale micropatterned engineered in vitor tissue
WO2008069906A3 (en) Digital expression of gene analysis
EP1994142A4 (en) METHODS AND COMPOSITIONS FOR RAPID ISOLATION OF SMALL RNA MOLECULES
WO2006078645A3 (en) Heterologous polypeptide expression using low multiplicity of infection of viruses
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
GB2449772A (en) Large scale production of stem cells
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
NO20065115L (no) Cellulaer tillatende faktor for virus, og anvendelse derav
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
MX2007010332A (es) Metodos y composiciones para promover adhesion o migracion de celula endotelial.
CY1112746T1 (el) Κρυοσυντηρηση ηπατοκυτταρων
TW200716130A (en) Purified form of tanaproget
GB2450599A (en) Automated culture of stem cells
ATE541855T1 (de) Weitere kristalline formen von rostafuroxin
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
BR0308736A (pt) Células de pulmão de rato cotton para cultura de vìrus
WO2008118871A3 (en) Methods of detecting inhibitors of vif-mediated apobec3g degradation and hiv
MY147959A (en) Productivity augmenting protein factor, novel cell lines and uses thereof
WO2006088747A3 (en) Serum-free reagents for the isolation, cultivation, and cryopreservation of postnatal pluripotent epiblast-like stem cells
EP1383866A4 (en) CULTURE SYSTEMS OF TRACHEAL MICE EPITHELIUM CELLS
IL165626A0 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
WO2007120298A3 (en) Methods, substrates and probes for assaying n-glycosidase activity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161216